Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Pfizer’s stock took a sharp dip on May 28, dropping over 2% to $23.12 by the afternoon. The stock opened flat at $23.61 but ...

Pfizer Limited’s stock price surged 28% last month and 18% over the past year, raising eyebrows despite subdued future growth ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

Pfizer’s stock surged up to 11 percent after the pharma giant reported a robust 85 percent year-on-year rise in net profit ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ: CORT) stands against ...